Erbitux Inquiry Could Yield Pre-Approval Speech Bill – Rep. Greenwood
Executive Summary
The House Energy & Commerce Committee is still interested in pursuing legislation to increase FDA's authority to regulate pre-approval promotions as a follow-up to the Erbitux investigation
You may also be interested in...
The Omniscient Regulator: QRxPharma’s Unusual Take on FDA and Investor Calls
Investor calls routinely begin with a disclaimer that the call is being recorded. They don’t usually include a warning that “FDA is monitoring the call.” But that is how QRxPharma began a discussion of a bad news event for its MoxDuo application.
FDA/SEC Communication Will Be “Systematized” In Response To Erbitux
FDA's Good Review Management Practices guidance will formalize communications with SEC regarding potentially misleading statements made by sponsors in the preapproval stage, Acting Commissioner Crawford told the House Energy & Commerce/Oversight Subcommittee Oct. 10
FDA/SEC Communication Will Be “Systematized” In Response To Erbitux
FDA's Good Review Management Practices guidance will formalize communications with SEC regarding potentially misleading statements made by sponsors in the preapproval stage, Acting Commissioner Crawford told the House Energy & Commerce/Oversight Subcommittee Oct. 10